| Drug General Information |
| Drug ID |
D08IRR
|
| Former ID |
DIB005642
|
| Drug Name |
Org-10490
|
| Indication |
Psychotic disorders [ICD9: 290-299; ICD10:F20-F29]
|
Terminated |
[1]
|
|---|
| Company |
Organon BioSciences
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
O1c2c(CCN(CCc3c1cccc3)C)cccc2.C(=O)(/C=C\C(=O)O)O
|
| CAS Number |
CAS 83507-03-3
|
| Target and Pathway |
| Target(s) |
Dopamine D1 receptor |
Target Info |
Modulator |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Morphine addiction
|
|
Alcoholismhsa04015:Rap1 signaling pathway
|
|
Alcoholism
|
|
PANTHER Pathway
|
Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
PathWhiz Pathway
|
Dopamine Activation of Neurological Reward System
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | ORG 10490: A new antipsychotic drug with 5-HT2 and DA antagonistic properties. ScienceDirect, Volume 6, Issue 2, January 1992, Pages 111. |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
|---|
